Loading...

LQDA LIQUIDIA CORP US FDA Inspections 8-K Filing

LQD

LQD

LIQUIDIA CORP

(LQDA)

2024 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Equity Offerings

Clinical Trials

Financial Results

Financing Agreement

Lease Extension

Financial Results

Patent Appeal Denied

Licensing Expansion

Legal Challenge

Financing Agreement Update

FDA Approval Update

Financial Results Announcement

Annual Meeting of Stockholders

Lawsuit Outcome

Complaint from United Thera...

Departure of Directors or C...

Financial Results Announcement

Injunction Set Aside for YU...

Financial Results Announcement

Update on New Drug Application

Management Changes

Unregistered Sales of Equit...

Financing Agreement and Pri...

Court Decision Affirmed

Equity Securities Sale

Entry into Material Definit...

Patent Infringement Allegat...

Patent Infringement Defense

Financial Results Announcement

Patent Litigation

Financial Results Announcement

Agreement Amendment

Agreement with Lonza for ma...

Regulation FD Disclosure

License Agreement with Phar...

Annual Meeting of Stockholders

Supply Agreement with Plast...

Earnings Reports

Research License Agreement ...

Other Special Situation

Agreement Amendment

Patent Decision

Termination of Loan Agreement

Entry Into a Material Defin...

External Links:

Liquidia Corp received tentative FDA approval for its inhalation powder YUTREPIA for pulmonary arterial hypertension, but final approval is delayed until after May 23, 2025, due to exclusivity granted to Tyvaso DPI.

AI Assistant

LIQUIDIA CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.